CIP, Cancer Immunology Project

Forwarded from NIIMA, Network of Immunity in Infection, Malignancy and Autoimmunity

Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?

New paper by USERN interest groups

🌀Ovarian cancer is one of the most common causes of mortality throughout the world.

🌀Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy.

🌀Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems.

🌀Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer.

To read the full paper:
https://www.futuremedicine.com/doi/abs/10.2217/nnm-2018-0379?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=nnm

#Paper

@niima_usern
@cip_usern
@usern_net

www.tgoop.com/CIP_USERN/110

28 viewsSep 8, 2019 at 07:04

Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?

New paper by USERN interest groups

🌀Ovarian cancer is one of the most common causes of mortality throughout the world.

🌀Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy.

🌀Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems.

🌀Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer.

To read the full paper:
https://www.futuremedicine.com/doi/abs/10.2217/nnm-2018-0379?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=nnm

#Paper

@niima_usern
@cip_usern
@usern_net

BY CIP, Cancer Immunology Project